Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT04133051Phase 2Completed
Phase 2, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by National Cancer Institute. Primary endpoint: Visual Analogue Scale at 48 hours. Started Nov 2018; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT04133051.